Nektar Therapeutics grants director 2,000 stock units

The RSUs vest in full one year following September 23, 2026; the option vests in substantially equal monthly installments over the one-year period beginning that date.

Available on EDGAR 09/25/2026 - 08:19 PM EDT Accepted by SEC EDGAR 09/25/2026 - 08:18 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

NEKTAR THERAPEUTICS director Jeffrey Robert Ajer received 2,000 restricted stock units and an option covering 4,000 common shares on September 23, 2026. The reported direct common-stock position following the RSU award was 4,277 shares. Each RSU represents a contingent right to one common share upon vesting.

The RSUs vest in full one year following September 23, 2026; the option vests in substantially equal monthly installments over the one-year period beginning that date. The option has a $57.66 per-share exercise price and expires September 22, 2034. The reported securities amounts reflect the one-for-fifteen reverse stock split effected June 8, 2025.

Insider Trade Summary

Grant/Award: 6,000 shares

Grant/Award 2 txns

Insider Ajer Jeffrey Robert

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option ^F4	4,000	$0.00	$0.00
Grant/Award	Common Stock ^{F1, F2, F3}	2,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 4,000 options (Direct); Common Stock — 4,277 shares (Direct)

Holdings Before and After: Stock Option, 0 to 4,000 options (Direct); Common Stock, 2,277 to 4,277 shares (Direct)

Footnotes (4)

F1. Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2. This RSU award vests in full, one year following September 23, 2026.
F3. On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
F4. This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.

Key Figures

Restricted stock units awarded: 2,000 restricted stock units Direct common-stock position: 4,277 shares Option award: 4,000 options +3 more

6 metrics

Restricted stock units awarded 2,000 restricted stock units Each represents a contingent right to receive one common share upon vesting.

Direct common-stock position 4,277 shares Reported following the RSU award.

Option award 4,000 options Each option covers one common share.

Exercise price $57.66 per share Price for the option award.

Option expiration September 22, 2034 Expiration date of the option award.

Reverse stock split One-for-fifteen Effected June 8, 2025; listed securities amounts were adjusted for the split.

Key Terms

restricted stock units, contingent right, substantially equal monthly installments, Reverse Stock Split

4 terms

restricted stock units financial

"grant of restricted stock units ("RSUs")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each RSU awarded represents a contingent right to receive"

substantially equal monthly installments financial

"vests in substantially equal monthly installments"

Reverse Stock Split financial

"one-for-fifteen reverse stock split of its common stock"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

Stock Split

1-for-15 reverse split · Effective June 8, 2025

Split Ratio 1-for-15 reverse split

Effective Date June 8, 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NEKTAR THERAPEUTICS director Jeffrey Robert Ajer receive?

Jeffrey Robert Ajer, a director of NEKTAR THERAPEUTICS, received 2,000 restricted stock units and an option covering 4,000 common shares on September 23, 2026. His reported direct common-stock position following the RSU award was 4,277 shares.

When do the NEKTAR THERAPEUTICS awards vest?

The 2,000 RSUs vest in full one year following September 23, 2026. The option covering 4,000 common shares vests in substantially equal monthly installments over the one-year period beginning September 23, 2026.

What are the exercise price and expiration date of Ajer's NEKTAR option?

The option has a $57.66 per-share exercise price and expires September 22, 2034.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ajer Jeffrey Robert

(Last)

(First)

(Middle)

C/O NEKTAR THERAPEUTICS

455 MISSION BAY BLVD SOUTH

(Street)

SAN FRANCISCO

CALIFORNIA

94158

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEKTAR THERAPEUTICS [ NKTR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽¹⁾	09/23/2026	⁽²⁾	A		2,000	A	$0.00	4,277⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$57.66	09/23/2026		A		4,000		⁽⁴⁾	09/22/2034	Common Stock	4,000	$0.00	4,000	D

Explanation of Responses:

1. Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.

2. This RSU award vests in full, one year following September 23, 2026.

3. On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.

4. This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.

	Elizabeth Zhang, Attorney-in-Fact	09/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR